BАbykids Spray In Common Cold

Not Applicable

Completed

• Conditions: Common Cold; Rhinitis Viral
• Interventions: Device: Placebo; Device: Healsea Babykids

• Registration Number: NCT05819203
• Lead Sponsor: Lallemand Pharma AG

Brief Summary

The purpose of this post market clinical investigation is to demonstrate that Healsea® Babykids alleviates symptoms of the acute rhinitis phase with better efficacy than isotonic saline solution used as Placebo in children above 2 years.

Detailed Description

Healsea® Babykids is an isotonic saline solution based nasal spray supplemented with a natural Symbiofilm® extract (0.04%) isolated from marine bacteria. Symbiofilm® has in vitro antibiofilm activity and protects in vitro human nasal epithelial cells viability after Rhinovirus, Adenovirus, coronavirus OC43 and flu infection.

Healsea® Babykids is a nasal spray indicated in children above 2 years to clean and moisten the nose during colds and rhinitis.

The common cold is an acute viral infection of the upper respiratory tract, involving, to variable degrees, sneezing, nasal congestion and discharge (rhinorrhea), sore throat, cough, low-grade fever, headache, and malaise. Acute viral rhinitis is generally self-limiting. In children where the illness is not self-limiting and extends beyond 7-10 days, many agree that a bacterial infection is likely. Bacterial over infections and progression to a chronic state are favoured by the formation of biofilms, which facilitate bacterial growth and persistence as well as reducing antibiotic efficacy.

The aim of this study is to demonstrate that Healsea® Babykids alleviates symptoms of the acute rhinitis phase with better efficacy than isotonic saline solution used as Placebo.

The study comprises 2 parts:

- Part 1 (Day 1-Day 11): treatment of the acute phase

• with Healsea® Babykids, 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes of Healsea® Babykids) up to 10 days (20 intakes of the investigational device).

or • with isotonic nasal spray (Placebo), 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes of Placebo) up to 10 days (20 intakes of the investigational device).

- Part 2 (up to Day 15/Day 18): follow-up phase.

The study comprises two visits:

* Visit 1 (V1) at Day 1

* End of study visit (Visit 2, V2) between Day 15 and Day 18

Study Timeline

• Study Start: 2023-02-13
• Study First Submitted: 2023-03-09
• Status Verified: 2023-04
• Study First Submitted QC: 2023-04-05
• Study First Posted: 2023-04-19
• Primary Completion: 2023-05-16
• Study Completion: 2023-05-16
• Results First Submitted: 2024-01-04
• Results First Submitted QC: 2024-07-04
• Last Update Submitted: 2024-07-04
• Results First Posted: 2024-10-07
• Last Update Posted: 2024-10-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• 1. Male/Female subjects >2 and ≤6-year-old
• 2. Acute infectious rhinitis/rhinosinusitis for ≤48h before trial entry
• 3. Patient presenting with fever ≥ 37.5 °C at screening
• 4. Subjects with nasal congestion (blocked / stuffy nose) rated at least as moderate on the Acute Rhinitis Symptoms Severity Questionnaire, based on evaluation by the investigator
• 5. Subjects showing at least moderate grade for at least one of the following additional signs of acute rhinitis: runny nose, nasal crust (dry mucus), sneezing and cough
• 6. Written consent obtained from parent/legal guardians

Exclusion Criteria

• 1. Known hypersensitivity/allergy to any component of the test device
• 2. Medical history that is considered by the investigator as a reason for non-inclusion,
• 3. Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps
• 4. History of nasal or sinus surgery that in the opinion of the investigator may influence symptom scores
• 5. Antibiotic intake within 2 weeks before screening
• 6. Systemic corticosteroids within 4 weeks before screening
• 7. Chronic decongestant use
• 8. Recent (within the previous 2 days) intake of a common cold medicine that in the opinion of the investigator may influence ARSSQ score at screening (NSAID, nasal decongestants, cough medicines)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	The comparator is a saline isotonic nasal spray considered as inert Placebo i.e., neutral for the nasal mucosa. Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes ).
Healsea Babykids	Healsea Babykids	Healsea® Babykids, nasal spray indistinguishable from the comparator. Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes ).

Primary Outcome Measures

Name	Time	Method
The Area Under the Curve (AUC) of the Global Score of the Acute Rhinitis Symptoms Severity Questionnaire (ARSSQ) During First 10 Days of Symptoms - Full Analysis Set (FAS)	From Day 1 to Day 10	ARSSQ is a non-validated customized questionnaire. It includes 10 items assessing symptoms (questions 2 to 7), functional impairments (8 to 10), and global severity (question 1). Each item is scored from 0 (not present/no impact/ not sick) to 3 (severe, severe impact and very sick) for symptoms, functional impairment and global severity respectively. The questionnaire is to be completed in a diary once daily in the evening.; The minimum ARSSQ score is zero (0) and the maximum ARSSQ score is thirty (30).
The Area Under the Curve (AUC) of the Global Score of the Acute Rhinitis Symptoms Severity Questionnaire (ARSSQ) During First 10 Days of Symptoms - Per Protocol Set (PP)	From Day 1 to Day 10	ARSSQ is a non-validated customized questionnaire. It includes 10 items assessing symptoms (questions 2 to 7), functional impairments (8 to 10), and global severity (question 1). Each item is scored from 0 (not present/no impact/ not sick) to 3 (severe, severe impact and very sick) for symptoms, functional impairment and global severity respectively. The questionnaire is to be completed in a diary once daily in the evening.; The minimum ARSSQ score is zero (0) and the maximum ARSSQ score is thirty (30).

Secondary Outcome Measures

Name	Time	Method
Duration of Each Cold Symptom (Questions 2 to 7 of the ARSSQ) in Both Groups	Through study completion, up to Day 18	For each separate symptom, the duration is defined as the number of days between Day 1 and the first day the parent/legal guardian reports the patient not having this symptom ("Not present") for 2 consecutive days.; Duration may be censored at Visit 2.
Duration of Quality-of-life Impairment (Questions 8 to 10 of the ARSSQ).	Through study completion, up to Day 18	For each separate symptom, the duration is defined as the number of days between Day 1 and the first day the parent/legal guardian reports the patient not having this symptom ("Not present") for 2 consecutive days.; Duration may be censored at Visit 2.
Cumulative Number of Days of Concomitant Treatments Use That May Affect Common Cold Symptoms (Antibiotics, Antipyretics, Systemic or Local Mucolytics, Decongestants, Antitussives, Systemic and Topical Corticosteroids)	Through study completion, up to Day 18	Concomitant treatments use (antibiotics, antipyretics, systemic or local mucolytics, decongestants, antitussives, systemic and topical corticosteroids) will be reported in the paper diary by parents/legal guardians throughout the study, validated by the investigator at the end of the study visit before being reported in the e-CRF.
Cumulative Number of Days of Antibiotics Intake	through study completion , up to day 18	Antibiotics use will be reported in the paper diary by parents/legal guardians throughout the study, validated by the investigator at the end of the study visit before being reported in the e-CRF.
Cumulative Number of Days of Antipyretics Intake	through study completion, up to day 18	Antipyretics use will be reported in the paper diary by parents/legal guardians throughout the study, validated by the investigator at the end of the study visit before being reported in the e-CRF.
Cumulative Number of Days of Mucolytics Intake	Through study completion , up to day 18	Mucolytics use will be reported in the paper diary by parents/legal guardians throughout the study, validated by the investigator at the end of the study visit before being reported in the e-CRF.
Cumulative Number of Days of Decongestants Use	through study completion, up to day 18	Decongestants use will be reported in the paper diary by parents/legal guardians throughout the study, validated by the investigator at the end of the study visit before being reported in the e-CRF.
Cumulative Number of Days of Antitussives Use	through study completion, up to day 18	Antitussives use will be reported in the paper diary by parents/legal guardians throughout the study, validated by the investigator at the end of the study visit before being reported in the e-CRF.
Cumulative Number of Days of Systemic and Topical Corticosteroids Use	Through study completion, up to day 18	Systemic and topical corticosteroids use will be reported in the paper diary by parents/legal guardians throughout the study, validated by the investigator at the end of the study visit before being reported in the e-CRF.

Trial Locations

Locations (1)

Medical center; 🇧🇬 Vratsa, Bulgaria